Company / SG&A per Share
UroGen Pharma Ltd. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$3.67
FY2025
5-year range
$2.87 / $3.95
FY2021-FY2025
Trend
+27.9%
vs FY2024
Sector context
#49 of 210
Health Care
What the data says
UroGen Pharma Ltd.'s sg&a per share of $3.67 is higher than 77% of companies in the Health Care sector (FY2025). SG&A per Share returned to growth in FY2025 after 3 years of decline, reaching $3.67.
Based on SEC 10-K filings.
3.67 in FY2025 with a 5-year CAGR of +5.1%. Top quartile in the Health Care sector.
Increased from $3.58 to $3.67 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 210This company $3.67 Sector average $40.75
▼
-91.0% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share increased 27.9% year-over-year.
- Ranks #49 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2021.
- Lowest sg&a per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.67 | +27.9% |
| FY2024 | $2.87 | -19.8% |
| FY2023 | $3.58 | -8.1% |
| FY2022 | $3.90 | -1.3% |
| FY2021 | $3.95 | +37.9% |
| FY2020 | $2.86 | +426.9% |
| FY2019 | $0.54 | -81.1% |
| FY2018 | $2.88 | +217.3% |
| FY2017 | $0.91 | -67.4% |
| FY2016 | $2.78 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026